drugset

drugset / Trial / NCT00717756

Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial

NCT00717756 ↗

Phase 2 Completed 41 enrolled Brown University Memorial Hospital of Rhode Island · collab Roger Williams Medical Center · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will determine whether lenalidomide has activity in patients with advanced liver cancer that have had growth of their cancer after sorafenib.

Timeline

Start: 2009-01
Primary completion: 2013-12
Completion: 2014-01

Publications

Results Safran H, Charpentier KP, Kaubisch A, Mantripragada K, Dubel G, Perez K, Faricy-Anderson K, Miner T, Eng Y, Victor J, Plette A, Espat J, Bakalarski P, Wingate P, Berz D, Luppe D, Martel D, Rosati K, Aparo S. Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study. Am J Clin Oncol. 2015 Feb;38(1):1-4. doi: 10.1097/COC.0b013e3182868c66.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lenalidomide	Other / unclassified	25 mg	Oral

Indications